Abstract
Background:
Circulating donor-derived cell-free DNA (dd-cfDNA) levels have been proposed as a potential tool for the diagnosis of graft injury. In this study, we prospectively investigated dd-cfDNA plasma levels and their association with severe primary graft dysfunction (PGD) and graft rejection after lung transplant.
Methods:
A total of 40 subjects undergoing de-novo lung transplants at our institution were recruited in this study. Blood samples were collected at various time points before and after lung transplant for 1 year. Dd-cfDNA in samples was determined using AlloSure assay (CareDx Inc.). The correlation of the value of %dd-cfDNA was investigated with the incidence of PGD, acute cellular rejection (ACR), and donor-specific antibody.
Results:
We observed a rapid increase of %dd-cfDNA in the blood of recipients after lung transplantation compared to baseline. The levels of dd-cfDNA decreased during the first two weeks. The peak was observed within 72 h after transplantation. The peak values of %dd-cfDNA varied among subjects and did not correlate with severe PGD incidence. We observed an association between levels of %dd-cfDNA from blood collected at the time of transbronchial biopsy and the histological diagnosis of ACR at 3 weeks.
Conclusion:
Our data show that circulating dd-cfDNA levels are associated with ACR early after transplantation but not with severe PGD. Plasma levels of dd-cfDNA may be a less invasive tool to estimate graft rejection after lung transplantation however larger studies are still necessary to better identify thresholds.
Introduction
Currently, most transplant centers monitor lung allograft quality through a combination of longitudinal transbronchial biopsies (TBBx) and pulmonary functional testing. However, given the heterogenous nature of acute cellular rejection, clinical needs for new donor graft diagnostic tools exist to know the posttransplant graft conditions and rejection more accurately and quantitatively in a non-invasive or less-invasive manner compared to the current standard practice in lung transplantation (, ). Liquid biopsy is a less invasive means to potentially measure graft damage, however, the donor-specific damage markers have not been found out with demonstrating their clinical relevancy and direct association with allograft rejection or dysfunction in the acute or chronic phase ().
Cell-free DNA (cfDNA) has been reported as a biomarker of graft injury and cell death in general. Under homeostatic conditions, healthy individuals have a low abundance of circulating cfDNA; acute/chronic inflammatory diseases resulting in increased cell turnover leads to an increased abundance of circulating cfDNA (). The half-life of cfDNA is typically less than 1–2 h, thus it's detection in the circulation can be considered a time-sensitive biomarker of a disease state (). By differentiating donor and recipient-specific single nucleotide polymorphisms (SNPs) it is possible to determine the origin of circulating cfDNA (). This methodology has been proposed to detect circulating donor-derived cfDNA (dd-cfDNA) as a potential tool for the identification of graft injury (rejection, infection, ischemia/reperfusion injury) (). The proportion of circulating dd-cfDNA has been associated with the presence of allograft rejection after solid organ transplantation. In lung transplantation, there are some reports demonstrating the association of dd-cfDNA with allograft rejection, infection and primary graft dysfunction (PGD) (–). While previous reports utilized whole genome sequencing or targeted sequencing, the next generation of targeted gene sequencing assays have advantages in with accuracy, detection time, cost, and no requirement of donor genotype data (, ). The clinical grade of the next generation of targeted gene sequencing assay has already been tested for plasma biorepository samples of lung transplant patients and found the detected %dd-cfDNA was associated with allograft rejection (–). In this study, we prospectively investigated dd-cfDNA levels in recipients' plasma and their association with severe PGD at 72 h and acute allograft rejection after lung transplantation, using a clinically approved next generation of targeted gene sequencing assay.
Materials and methods
Study design
This was a single-center prospective observational study performed under the approval of the Institutional Review Board of the University of Pittsburgh (STUDY 19090098 approval: 12/2019; ClinicalTrials.gov Identifier: NCT04318587). Adults (>18 years-old, both male and female) undergoing de-novo lung transplantation at our institute were recruited in this study. The patients who had multi-organ transplants, bone-marrow transplants, and re-transplantation were excluded due to the detection mechanism of dd-cfDNA. All subjects were consented to the study before the transplantation. The blood samples from the consented subjects were obtained using a blood tube preserving the cfDNA (Cell-Free DNA BCT®; Streck Corporate, La Vista, NE) and scheduled to draw at pre-operation and postoperative day 1, 2, 3, once a week for 1–12 weeks, and once a month from 4 months to 12 months posttransplant (Figure 1A). After the subjects were discharged, the blood was drawn at the time of their follow-up visit.
Figure 1
Determination of dd-cfDNA
The dd-cfDNA were measured using the AlloSure assay (CareDx, Inc., Brisbane, CA). Allosure assay is a clinical-grade, next generation of targeted gene sequencing assay to measure SNPs to accurately quantify dd-cfDNA. All blood samples were shipped to the CareDx facility for the AlloSure assay. The dd-cfDNA data were provided as a percentage (%dd-cfDNA) of the total (donor + recipient) cfDNA.
Primary outcomes
The primary outcomes include the PGD grade, acute cellular rejection (ACR), and development of de-novo donor-specific antibody (DSA). The PGD grade for the first posttransplant 3 days was determined daily by the treating team, using the ISHLT criteria (). Our protocol includes a surveillance bronchoscopy with TBBx at 2–3 weeks post-transplant. ACR was diagnosed and graded by a pulmonary pathologist after evaluation of histopathology slides ().
After the subject discharging, allograft ACR was diagnosed by TBBx at the time of the subject's follow-up visit and was graded. At the same time as TBBx, blood was sampled for ddcfDNA for AlloSure assay and detecting DSA by the UPMC Histocompatibility Laboratory (). Positive DSA was determined with mean fluorescence intensity >1,000 in a single-antigen beads assay (LABScreen class I and II, One Lambda, West Hills, CA). We analyzed the %dd-cfDNA data to see the correlation with the ACR grade and the existence of de-novo DSA at the same time point.
Statistical analysis
Univariable analyses were performed using SPSS (v. 28.0, IBM, Armonk, NY). Results are shown as mean ± standard deviation (SD) with individual values or median and interquartile range (IQR). Univariable comparisons were performed using chi-square tests for categorical variables and Mann-Whitney U tests for continuous variables. Data with multiple groups were analyzed using one-way analysis of variance followed by post hoc analysis with the Tukey test for multiple comparisons. Multiple observations over time were analyzed using a two-way ANOVA mixed model. A probability level of p < 0.05 was considered statistically significant.
Results
Subject characteristics and posttransplant data
The patient characteristics and posttransplant data are summarized in Table 1. Forty patients (39 double lung transplants and 1 single lung transplant) were enrolled. All recipients were transplanted with grafts from brain death donors. 39 sequential double lung transplants and 1 single lung transplant were performed. One case used ex-vivo lung perfusion to evaluate a graft before transplant. The severe PGD incidence at 72 h posttransplant was 27.5% (n = 11). The mean duration of intensive care unit and hospital stay were 10.7 ± 12.9 and 27.3 ± 16.2 days, respectively (Table 2).
Table 1
| Total | No ACR | ACR1 > within a year | |
|---|---|---|---|
| Subject, n | 40 | 15 | 25 |
| Recipient characteristics | |||
| Recipient age [years-old], median (IQR) | 61.5 (15.3) | 61.0 (15.0) | 65.0 (9.0) |
| Recipient female, n (%) | 17 (42.5) | 11 (73.3) | 6 (24.0) |
| LAS, median (IQR) | 41.1 (10.5) | 41.2 (5.1) | 37.6 (11.3) |
| Recipient BMI (kg/m2), median (IQR) | 26.2 (6.3) | 26.7 (7.1) | 26.2 (5.7) |
| Recipient Diagnosis, n (%) | |||
| Obstructive | 11 (27.5) | 2 (13.3) | 9 (36.0) |
| Pulmonary vascular | 1 (2.5) | 1 (6.7) | 0 |
| Suppurative | 3 (7.5) | 1 (6.7) | 2 (8.0) |
| Restrictive | 25 (62.5) | 11 (73.3) | 14 (56.0) |
| Donor characteristics | |||
| Donor age [years-old], median (IQR) | 34.5 (16.0) | 37.0 (20.5) | 32.0 (14.0) |
| Brain death donors, n (%) | 40 (100) | 15 (100) | 25 (100) |
| Donor BMI [kg/m2], median (IQR) | 25.7 (7.7) | 27.1 (8.4) | 24.1 (6.9) |
| ex vivo lung perfusion, n (%) | 1 (2.5) | 1 (6.7) | 0 |
| Perioperative parameters | |||
| Total preservation time [min], median (IQR) | 387.0 (83.0) | 408.0 (82.5) | 385.0 (91.0) |
| Induction, n (%) | |||
| Simulect | 27 (67.5) | 11 (73.3) | 16 (64.0) |
| Campath | 13 (32.5) | 4 (26.7) | 9 (36.0) |
| Intraoperative support, n (%) | |||
| CPB | 23 (57.5) | 10 (66.7) | 13 (52.0) |
| ECMO | 12 (30.0) | 4 (26.7) | 8 (32.0) |
| None | 5 (12.5) | 1 (6.7) | 4 (16.0) |
| Intraoperative product volume (units), median (IQR) | 7.0 (8.3) | 7.0 (8.5) | 7.0 (7.0) |
Recipients and donors’ characteristics.
BMI, body mass index; CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenation; LAS, lung allocation score.
Table 2
| Double lung transplant, n (%) | 39 (97.5) |
| PGD3 at 24 h, n (%) | 8 (20.0) |
| PGD3 at 48 h, n (%) | 10 (25.0) |
| PGD3 at 72 h, n (%) | 11 (27.5) |
| CRRT within 1 week, n (%) | 3 (7.5) |
| Hepatic dysfunction, n (%) | 4 (10.0) |
| ICU stay, median (IQR) | 5.0 (9.5) |
| Hospital stay, median (IQR) | 22.5 (14.3) |
| De-novo DSA within a year, n (%) | 18 (45.0) |
| ACR 1 > at the first TBBX, n (%) | 13 (32.5) |
| ACR 1 > within a year, n (%) | 25 (62.5) |
Post-transplant data.
ACR, acute cellular rejection; CRRT, continuous renal replacement therapy; DSA, donor-specific antibody; ICU, intensive care unit; PGD3, primary graft dysfunction grade 3.
The time-dependent change of %dd-cfDNA circulating in the patient's blood after lung transplantation
A total of 515 samples were collected to determine %dd-cfDNA from the subjects. Twenty-four samples were rejected for the assay due to poor sample quality or the assay metrics issue. The time-dependent change of %dd-cfDNA in the first 3 months is shown in Figure 1B. The %dd-cfDNA in the circulation was elevated from baseline immediately after transplantation (pretransplant: mean ± SD 0.013 ± 0.05%) and showed a peak value (mean ± SD 15.5 ± 4.56%, range: 5.94–26.99%) within 48 h posttransplant. The %dd-cfDNA was decreased over 2 weeks and reached a plateau (stable) level (Figure 1B). There was no significant association between the lung allograft preservation time and the peak %dd-cfDNA (Figure 1C).
The association of dd-cfDNA level and the PGD incidence
We compared the circulating %dd-cfDNA between patients who developed PGD grade 3 and those who with grade 0–2, with the hypothesis that lungs with severe PGD should exhibit a greater degree of allograft cellular death, releasing a higher plasma level of dd-cfDNA. Instead, we found a lower %dd-cfDNA at T48 h in the severe PGD cohort, and no difference in %dd-cfDNA at any other timepoints up to 4 weeks (Figure 2A). We next found no difference in the %dd-cfDNA based on grade of PGD (Figure 2B). Finally, we found no statistically significant association between the peak %dd-cfDNA with the PGD3 within 24–48 h posttransplant (Figure 2C).
Figure 2
The correlation of the %dd-cfDNA and graft rejection
At our institution, we perform the first TBBx within 2–3 weeks of transplantation to detect early ACR. We compared the %dd-cfDNA in the days to weeks after transplantation with the histopathological diagnosis of early ACR. When looking at longitudinal, timepoint matched values of circulating %dd-cfDNA, we found no statistically significant difference between those study participants who developed early ACR and those that did not (Figure 3A). However, we found a statistically significant increase in %dd-cfDNA in the plasma drawn from recipients posttransplant 2 weeks and the first TBBx showing early ACR (Figure 3B). Although statistically significant, there was substantial overlap between groups, and the upper limit of %dd-cfDNA in the early ACR group was well below levels found at 1 week after transplantation.
Figure 3
We next looked at the %dd-cfDNA compared to the presence of ACR and de-novo DSA diagnosed after discharging to 1-year follow-up period. We analyzed data to see the correlation of %dd-cfDNA with the ACR grade based on TBBx and the existence of de-novo DSA at the same time point. Contrary to recent reports about the association of antibody mediated rejection and %dd-cfDNA (), we found that %dd-cfDNA were not significantly higher in patients with de-novo DSA (Figure 3C). However, patients with both ACR and de-novo DSA had a significantly higher %dd-cfDNA than those without either (Figure 3C). Interestingly, other sources of allograft injury (bronchiolitis, sepsis, anastomosis stenosis, and pseudomonas pneumonia) had comparable elevation in %dd-cfDNA as those with both ACR and de-novo DSA. These findings suggest that %dd-cfDNA could not differentiate sources of perioperative lung injury.
Discussion
Potential disturbances for %dd-cfDNA as an early biomarker
We provisionally investigated the association of %dd-cfDNA determined by the next generation of gene sequence technology with early perioperative outcomes including the PGD, ACR, and de-novo DSA in recipients of lung transplantation. Regardless of PGD grade, most study participants had a substantial increase in the proportion of dd-cfDNA immediately after lung transplantation. Similar results have been observed in kidney transplantation and this is considered a result of ischemia-reperfusion injury (). While we observed the %dd-cfDNA reached the baseline level within 2 weeks and decreased at 86.5% from the peak value in this study, the trend of %dd-cfDNA could differ among the organ types. Studies in kidney transplant demonstrated that %dd-cfDNA converged to the plateau within a week (–), while the multicenter study “GRAfT” for heart transplants showed it reached the baseline by ∼60 days (). Allograft cell death should correlate with grade of ischemia-reperfusion injury and PGD after solid organ transplantation (). Our findings in lung transplant setting are not consistent with this hypothesis owing to 3 potential explanations. First is the nature of the test itself, measuring the proportion and not absolute value of the dd-cfDNA; second, is the systemic symptom of PGD3; and the third, is the unknown source of the cfDNA. As previously mentioned, the %dd-cfDNA is the ratio of dd-cfDNA among the total cfDNA circulating in the blood of recipients which is likely impacted by recipient-derived cfDNA, especially with inflammatory cell turnover. Thus, increased occupation of plasma recipient-derived cfDNA in response to systemic conditions can reduce the %dd-cfDNA proportionally (). While %dd-cfDNA is often utilized in clinical currently rather than the absolute copy or concentration of cfDNA, the quantification of dd-cfDNA copy may represent the PGD phenotype or rejection without recipients' noise (, ). Since this method measures the ratio, there is no method to normalize across patient characteristics or procedure-related biases (e.g., body size, patient condition, single/double lung transplant, blood transfusion).
Severe PGD is now appreciated to be a systemic condition which may impact the proportion of donor and recipient derived cfDNA (). Severest PGD patients are often comorbid with acute kidney failure or liver dysfunction and these lead patients to systemic illness and require additional life support therapy (, ). Some of our subjects with severe PGD showed critical illness in this study and required hemodialysis in addition to extracorporeal membrane oxygenation (ECMO). These factors could affect both recipient and total DNA levels and create potential bias on %dd-cfDNA through material-biological interaction, increased recipient-derived cfDNA, and elimination of DNA by hemodialysis (–). Further basic investigations are required to clarify the effects of these disturbances on the net cfDNA and the diagnosis power of dd-cfDNA for posttransplant graft outcomes in lung transplantation.
Another important aspect of our finding is that the spike of the %dd-cfDNA was observed in the non-PGD group as well, suggesting this cellular death is not associated with graft injury and dysfunction. undetectable cellular source of cfDNA is one of the limitations of the bulk dd-cfDNA assay, thus we could not know whether the dd-cfDNA was resulting from the tissue injury after ischemia-reperfusion, or just washing out effects of the remnant cfDNA carried over from the donors in grafts. While the vascular bed of grafts is washed by antegrade and retrograde flushing at procurement, some donor cells [aka. microchimerism ()] and other blood components could remain in the allografts (, ). Therefore, the dd-cfDNA released from the allografts immediately after transplantation could contain multiple factors, and determining the source of the dd-cfDNA within the first 3 days is of interest to define its association with the allograft damage and increase the graft specificity ().
Acute graft rejection and %dd-cfDNA
We observed significantly increased %dd-cfDNA was associated with ACR alone and combined allograft rejection (ACR + de-novo DSA), but not de-novo DSA alone. Despite these statistically significant increases in %dd-cfDNA with both ACR and combined rejection, the percentage point increases were small; the majority had less than 2% in most cases. This modest increase in %dd-cfDNA does not provide us much insight into the relationship between graft cell death and the alloreactive response. It is entirely possible that rate of graft cell death occurs much more slowly in the setting of allorecognition (). Alternatively, the low proportion of %dd-cfDNA in the setting of rejection represents a concomitant increase in circulating cfDNA of both donor graft cell death and recipient-derived immune cell turnover, leading to variable and modest changes in the circulating %dd-cfDNA. As mentioned, the lifetime of cfDNA in blood circulation is usually 1–2 h, thus it is hard to capture a slow-progressing cellular death in grafts by detecting dd-cfDNA. Multi-factorial rejection may enhance cell death in grafts thus the %dd-cfDNA has responded higher in the mixed allograft damage than the single factor rejection.
Ultimately, the limited range of circulating %dd-cfDNA in the setting of early allograft rejection raises questions about the ability of circulating %dd-cfDNA to identify specific patterns of allograft injury with any degree of resolution and sensitivity. This poor resolution as a diagnostic tool has been reported in other solid organ transplants, with levels range above 1.0% of dd-cfDNA for a risk of active rejection, especially above 0.5% for lung transplantation (). Not only the graft rejection, the %dd-cfDNA in lung transplantation could correlate with exogenous and endogenous effectors, such as aspiration, bronchiolitis, infection, or malignancy, which augment mass cell death. Thus, the %dd-cfDNA can supplementally be important to support diagnosing graft rejection with TBBx, DSA detection, or other conventional tools. More sophisticated means of determining the cellular origin of circulating cfDNA used in concert with other metrices may provide the detection of dd-cfDNA the granularity needed to be a clinical useful biomarker. However, as it remains now, the %dd-cfDNA does not provide the precision necessary to justify broad clinical utilization.
Limitations
There are several limitations of dd-cfDNA study in general. Without performing the donor genotyping, the next generation of gene sequencing technology cannot identify the dd-cfDNA in the patient plasma after re-transplantation, multi-organ transplantation, and bone marrow Tx case. In addition, we were not able to get the %dd-cfDNA data for 24 samples out of 515 samples, because of the sample quality and the assay quality metrics issue. One of the biggest issues in the sample quality is hemolysis and hemolysis can happen with improper sampling in general or a longer sample storage in the tube [>5 days ()], or it may be originated in the patients due to ECMO, cardiopulmonary bypass, blood transfusion or hemodialysis. This may result in an increase in the background recipient-derived cfDNA, thus those samples were rejected from the assay ().
Conclusion
Our data show that circulating %dd-cfDNA did not show a relevant association with PGD, suggesting potential room to refine this technology in order to become a better biomarker for acute graft injury. Plasma levels of dd-cfDNA may be a less invasive tool to estimate graft rejection after lung transplantation however larger studies are still necessary to better identify thresholds.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by the Institutional Review Board at the University of Pittsburgh. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
KN: Data curation, Formal Analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing. MS: Data curation, Validation, Writing – original draft, Writing – review & editing. QX: Data curation, Validation, Writing – review & editing. DP: Conceptualization, Methodology, Writing – review & editing. JM: Conceptualization, Funding acquisition, Supervision, Writing – review & editing. AZ: Conceptualization, Data curation, Funding acquisition, Project administration, Supervision, Validation, Writing – review & editing, Formal Analysis, Investigation, Methodology, Resources. PS: Conceptualization, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review & editing, Data curation, Formal Analysis, Investigation, Methodology, Resources, Validation.
Funding
The authors declare financial support was received for the research, authorship, and/or publication of this article.
This study was supported by an investigator-initiated research grant from the CareDx (Ref: UPMC001 “Assessment of Donor Derived Cell-Free DNA and Utility in Lung Transplantation”).
Acknowledgments
We thank Naomi Ryssel, MPH (University of Pittsburgh) and Jennifer Gray, PharmD (CareDx, Inc.) for organizing our investigator-initiated clinical study, and CareDx company to determine and provide us the %dd-cfDNA by the AlloSure® assay.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
GreerMWerleinCJonigkD. Surveillance for acute cellular rejection after lung transplantation. Ann Transl Med. (2020) 8(6):410. 10.21037/atm.2020.02.127
2.
VerledenSEHendriksJMHLauwersPYogeswaranSKVerplanckeVKwakkel-Van-ErpJM. Biomarkers for chronic lung allograft dysfunction: ready for prime time?Transplantation. (2023) 107(2):341–50. 10.1097/TP.0000000000004270
3.
RosenheckJPKellerBCFehringerGDemkoZPBohradeSMRossDJ. Why cell-free DNA can be a “game changer” for lung allograft monitoring for rejection and infection. Curr Pulmonol Rep. (2022) 11(3):75–85. 10.1007/s13665-022-00292-8
4.
HeitzerEAuingerLSpeicherMR. Cell-free DNA and apoptosis: how dead cells inform about the living. Trends Mol Med. (2020) 26(5):519–28. 10.1016/j.molmed.2020.01.012
5.
KustanovichASchwartzRPeretzTGrinshpunA. Life and death of circulating cell-free DNA. Cancer Biol Ther. (2019) 20(8):1057–67. 10.1080/15384047.2019.1598759
6.
KellerMAgbor-EnohS. Donor-derived cell-free DNA for acute rejection monitoring in heart and lung transplantation. Curr Transplant Rep. (2021) 8(4):351–8. 10.1007/s40472-021-00349-8
7.
De VlaminckIMartinLKerteszMPatelKKowarskyMStrehlCet alNoninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci U S A. (2015) 112(43):13336–41. 10.1073/pnas.1517494112
8.
TanakaSSugimotoSKurosakiTMiyoshiKOtaniSSuzawaKet alDonor-derived cell-free DNA is associated with acute rejection and decreased oxygenation in primary graft dysfunction after living donor-lobar lung transplantation. Sci Rep. (2018) 8(1):15366. 10.1038/s41598-018-33848-3
9.
Agbor-EnohSWangYTuncIJangMKDavisADe VlaminckIet alDonor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation. EBioMedicine. (2019) 40:541–53. 10.1016/j.ebiom.2018.12.029
10.
KellerMBushEDiamondJMShahPMatthewJBrownAWet alUse of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD). J Heart Lung Transplant. (2021) 40(6):488–93. 10.1016/j.healun.2021.02.008
11.
GrskovicMHillerDJEubankLASninskyJJChristophersonCCollinsJPet alValidation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. (2016) 18(6):890–902. 10.1016/j.jmoldx.2016.07.003
12.
KhushKKDe VlaminckILuikartHRossDJNicollsMR. Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation. ERJ Open Res. (2021) 7(1):00462–2020. 10.1183/23120541.00462-2020
13.
SayahDWeigtSSRamseyAArdehaliAGoldenJRossDJ. Plasma donor-derived cell-free DNA levels are increased during acute cellular rejection after lung transplant: pilot data. Transplant Direct. (2020) 6(10):e608. 10.1097/TXD.0000000000001063
14.
RosenheckJPRossDJBotrosMWongASternbergJChenYAet alClinical validation of a plasma donor-derived cell-free DNA assay to detect allograft rejection and injury in lung transplant. Transplant Direct. (2022) 8(4):e1317. 10.1097/TXD.0000000000001317
15.
SnellGIYusenRDWeillDStrueberMGarrityEReedAet alReport of the ISHLT working group on primary lung graft dysfunction, part I: definition and grading—a 2016 consensus group statement of the international society for heart and lung transplantation. J Heart Lung Transplant. (2017) 36(10):1097–103. 10.1016/j.healun.2017.07.021
16.
StewartSFishbeinMCSnellGIBerryGJBoehlerABurkeMMet alRevision of the 1996 working formulation for the standardization of Nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. (2007) 26(12):1229–42. 10.1016/j.healun.2007.10.017
17.
IasellaCJEnsorCRMarrariMMangiolaMXuQNolleyEet alDonor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction. J Heart Lung Transplant. (2020) 39(12):1417–25. 10.1016/j.healun.2020.09.003
18.
SeetoRKFlemingJNDholakiaSDaleBL. Understanding and using AlloSure donor derived cell-free DNA. Biophys Rev. (2020) 12(4):917–24. 10.1007/s12551-020-00713-5
19.
GielisEMBeirnaertCDendoovenAMeysmanPLaukensKDe SchrijverJet alPlasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay. PLoS One. (2018) 13(12):e0208207. 10.1371/journal.pone.0208207
20.
ShenJZhouYChenYLiXLeiWGeJet alDynamics of early post-operative plasma ddcfDNA levels in kidney transplantation: a single-center pilot study. Transpl Int. (2019) 32(2):184–92. 10.1111/tri.13341
21.
NieWSuXLiuLLiJFuQLiXet alDynamics of donor-derived cell-free DNA at the early phase after pediatric kidney transplantation: a prospective cohort study. Front Med (Lausanne). (2021) 8:814517. 10.3389/fmed.2021.814517
22.
Agbor-EnohSShahPTuncIHsuSRussellSFellerEet alCell-free DNA to detect heart allograft acute rejection. Circulation. (2021) 143(12):1184–97. 10.1161/CIRCULATIONAHA.120.049098
23.
KanouTNakahiraKChoiAMYeungJCCypelMLiuMet alCell-free DNA in human ex vivo lung perfusate as a potential biomarker to predict the risk of primary graft dysfunction in lung transplantation. J Thorac Cardiovasc Surg. (2021) 162(2):490–9.e2. 10.1016/j.jtcvs.2020.08.008
24.
KimPJOlymbiosMSiuAWever PinzonOAdlerELiangNet alA novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation. J Heart Lung Transplant. (2022) 41(7):919–27. 10.1016/j.healun.2022.04.002
25.
OellerichMShipkovaMAsendorfTWalsonPDSchauerteVMettenmeyerNet alAbsolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: results from a prospective observational study. Am J Transplant. (2019) 19(11):3087–99. 10.1111/ajt.15416
26.
OsmanodjaBAkifovaABuddeKChoiMOellerichMSchützEet alAbsolute or relative quantification of donor-derived cell-free DNA in kidney transplant recipients: case series. Transplant Direct. (2021) 7(11):e778. 10.1097/TXD.0000000000001237
27.
DiamondJMLeeJCKawutSMShahRJLocalioARBellamySLet alClinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. (2013) 187(5):527–34. 10.1164/rccm.201210-1865OC
28.
HyznyEJChanEGMalikSMMorrellMFurukawaMRyanJPet alRisk factors and outcomes of postoperative hepatic dysfunction after lung transplantation. Ann Thorac Surg. (2022) 116(6):1277–84. 10.1016/j.athoracsur.2022.08.047
29.
ChanEGPanGCliffordSHyznyEJFurukawaMCosterJNet alPostoperative acute kidney injury and long-term outcomes following lung transplantation. Ann Thorac Surg. (2023) 116(5):1056–62. 10.1016/j.athoracsur.2023.06.016
30.
García MoreiraVde la Cera MartínezTGago GonzálezEPrieto GarcíaBAlvarez MenéndezFV. Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR. Clin Chem Lab Med. (2006) 44(12):1410–5. 10.1515/CCLM.2006.252
31.
RumorePMuralidharBLinMLaiCSteinmanCR. Haemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearance. Clin Exp Immunol. (2008) 90(1):56–62. 10.1111/j.1365-2249.1992.tb05831.x
32.
SayahDMMallaviaBLiuFOrtiz-MuñozGCaudrillierADerHovanessianAet alNeutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. (2015) 191(4):455–63. 10.1164/rccm.201406-1086OC
33.
DemetrisAJMuraseNRaoASFungJJStarzlTE. The dichotomous functions of passenger leukocytes in solid-organ transplantation. Adv Nephrol Necker Hosp. (1995) 24:341–54.
34.
StoneJPCritchleyWRMajorTRajanGRisnesIScottHet alAltered immunogenicity of donor lungs via removal of passenger leukocytes using ex vivo lung perfusion. Am J Transplant. (2016) 16(1):33–43. 10.1111/ajt.13446
35.
TsujiNAgbor-EnohS. Cell-free DNA beyond a biomarker for rejection: biological trigger of tissue injury and potential therapeutics. J Heart Lung Transplant. (2021) 40(6):405–13. 10.1016/j.healun.2021.03.007
36.
HansenPRHolmAMSvendsenUGOlsenPSAndersenCB. Apoptosis in acute pulmonary allograft rejection and cytomegalovirus infection. APMIS. (1999) 107(1–6):529–33. 10.1111/j.1699-0463.1999.tb01589.x
37.
TrindadeAJChapinKCMullicanAGrayJNHoyHDemarestCTet alAssessment of dd-cfDNA levels in clinically stable lung allograft recipients beyond the initial 2 y posttransplant. Transplant Direct. (2022) 8(12):e1411. 10.1097/TXD.0000000000001411
38.
Gahlawat AWLenhardtJWitteTKeitelDKaufholdAMaassKKet alEvaluation of storage tubes for combined analysis of circulating nucleic acids in liquid biopsies. Int J Mol Sci. (2019) 20(3):704. 10.3390/ijms20030704
39.
NishimuraFUnoNChiangPCKakuNMorinagaYHasegawaHet alThe effect of in vitro hemolysis on measurement of cell-free DNA. J Appl Lab Med. (2019) 4(2):235–40. 10.1373/jalm.2018.027953
Summary
Keywords
lung transplantation, donor-derived cell-free DNA, primary grafts dysfunction, acute cellular rejection, antibody-mediated rejection
Citation
Noda K, Snyder ME, Xu Q, Peters D, McDyer JF, Zeevi A and Sanchez PG (2024) Single center study investigating the clinical association of donor-derived cell-free DNA with acute outcomes in lung transplantation. Front. Transplant. 2:1339814. doi: 10.3389/frtra.2023.1339814
Received
16 November 2023
Accepted
29 December 2023
Published
11 January 2024
Volume
2 - 2023
Edited by
Markus Kamler, Essen University Hospital, Germany
Reviewed by
Achim Koch, Essen University Hospital, Germany
Karl Lemstrom, University of Helsinki, Finland
Updates
Copyright
© 2024 Noda, Snyder, Xu, Peters, McDyer, Zeevi and Sanchez.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Pablo G. Sanchez sanchezpg@upmc.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.